Business Coordinator, PhD
University of Eastern Finland
Dr Nigel R Parker (PhD) is a scientist with 40 years pharmaceutical and finance experience in both private and public sectors. His translational experience in the ATMP’ sector includes 4 Phase 3, 6 Phase 1/2a and 1 Phase 0 studies, filing the first gene medicine MAA application and pioneering regulatory standards and regulations for gene medicine with EMA. He is an inventor on numerous fundamental industry gene therapy patents in cardiovascular, cancer, vector, assay and manufacturing. With some $3.5bn of financial transactions including IPO’s in the USA and UK as well as many international mergers and acquisitions, he brings a strong translational and commercial focus to the GeneCellNano Flagship.